This meta-analysis confirms that corticosteroid use significantly increases the risk of depressive symptoms and acute manic episodes, prompting psychiatrists to monitor mood closely during high-dose or early-phase steroid therapy.
Centanafadine demonstrates statistically significant and clinically relevant improvements in ADHD symptoms, supporting its potential as a new treatment option for attention-deficit/hyperactivity disorder.
Centanafadine demonstrated efficacy in a clinical trial for ADHD with comorbid anxiety, marking a significant development in the pharmacotherapy of attention-deficit/hyperactivity disorder.
Definium Therapeutics released Phase 3 results for its LSD-based treatment for depression, marking a significant clinical trial readout in psychedelic psychiatry.
A randomized clinical trial published in the Journal of Psychopharmacology evaluates repeated doses of psilocybin as a treatment for obsessive-compulsive disorder.
Clinical Pearls
Bite-sized clinical takeaways from today's literature (sources from Mar 14 – Jun 28)
- Consider centanafadine as a novel non-stimulant option for patients with ADHD who also present with comorbid anxiety.
- Monitor mood closely in patients initiating high-dose corticosteroid therapy due to the significant risk of inducing depressive symptoms or acute manic episodes.
- Evaluate psilocybin as an emerging investigational treatment modality for obsessive-compulsive disorder based on recent randomized clinical trial data.
- Stay informed about definium therapeutics' phase 3 results for LSD-based depression treatments to anticipate future shifts in psychedelic psychiatry pharmacotherapy.
- Recognize that centanafadine offers statistically significant improvements in ADHD symptoms, supporting its potential role in the treatment algorithm.